Tenecteplase–Tissue-Type Plasminogen Activator Evaluation for Minor Ischemic Stroke With Proven Occlusion
Stroke2015Vol. 46(3), pp. 769–774
Citations Over TimeTop 10% of 2015 papers
Shelagh B. Coutts, Véronique Dubuc, Jennifer Mandzia, Carol Kenney, Andrew M. Demchuk, Eric E. Smith, Suresh Subramaniam, Mayank Goyal, Shivanand Patil, Bijoy K. Menon, Philip A. Barber, Dar Dowlatshahi, Thalia S. Field, Negar Asdaghi, Marie-Christine Camden, Michael D. Hill
Abstract
http://www.clinicaltrials.gov. Unique identifier: NCT01654445.
Related Papers
- → Tenecteplase versus alteplase in stroke thrombolysis: An individual patient data meta-analysis of randomized controlled trials(2016)84 cited
- → Treatment times, functional outcome, and hemorrhage rates after switching to tenecteplase for stroke thrombolysis: Insights from the TETRIS registry(2022)39 cited
- → Abstract TMP24: Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)(2018)4 cited
- → Intravenous thrombolysis by tenecteplase: Experience of the neurology department of Chu Hassan II Fez, Morocco(2019)
- → OUTCOME OF INTRAVENOUS THROMBOLYSIS WITH TENECTEPLASE IN ACUTE ISCHEMIC STROKE.(2022)